Skip to main content
Clinical Trials/NCT03904485
NCT03904485UnknownNot Applicable

Assessment of Myocardial Injury in Recipients of Simultaneous Pancreas and Kidney Transplantation

Tianjin First Central Hospital1 site in 1 country50 target enrollmentStarted: April 1, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
50
Locations
1
Primary Endpoint
Assessment of myocardial injury

Study Overview

Brief Summary

Diabetic cardiomyopathy( DCM) is a major complication of diabetes and is a common cardiovascular complication independent of coronary artery disease and hypertension.Trial to assess of myocardial injury in recipients of simultaneous pancreas and kidney transplantation by nuclear magnetic T2 mapping technology.

Detailed Description

  1. Evaluate the changes of myocardial injury before and after SPK by cardiac magnetic resonance imaging (CMR),
  2. Evaluate the value of SPK in the repair of myocardial injury by comparing with the single renal transplant in recipients with diabetic nephropathy.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
20 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • patients with type 2 diabetes were treated with SPK; 2.No definite history of cardiovascular diseases (such as congenital heart disease, coronary heart disease, cardiomyopathy or valvular heart disease, etc.);
  • Preoperative hemodialysis
  • No history of heart failure

Exclusion Criteria

  • Contraindications in cardiac magnetic resonance imaging;2.poorly controlled hypertension;3.CMR examination revealed marked hypertrophy of the left ventricular myocardium

Outcomes

Primary Outcomes

Assessment of myocardial injury

Time Frame: 1year

Assessment of myocardial injury between two groups

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Tianjin First Central Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Yingxin FU.MD

Director of kidney transplantation center

Tianjin First Central Hospital

Study Sites (1)

Loading locations...

Similar Trials